Dr. Hans Fliri, the Managing Director of Selcia said, "We are pleased to have this opportunity to develop our business as the only dedicated provider of custom radiolabeling, chemistry and analytics services to a worldwide customer base."
"The continuing rapid expansion of our business has provided us with the confidence to move forward as an independent company."
"We are already in the process of offering new services such as metabolomics and metabolic profiling, and their integration with chemistry."
Fliri continued, "Our service business is based on a track record of scientific excellence at the Ongar site and a skillful, highly committed staff."
"We plan to increase capacity in this business and to invest in new development programs in the future. This will create opportunities for new financial investment in the company."
"The transaction will allow Scynexis to concentrate on its core business and partners and will provide Selcia the opportunity to focus on its services," said Dr. Yves Ribeill, President and Chief Executive Officer of Scynexis, Inc.
"By doing so, Scynexis can enhance our growing presence in the global pharmaceutical marketplace and continue to build discovery collaborations with major companies."
Ribeill Added, "Scynexis extends its best wishes to Dr. Fliri and his highly qualified team."